Datasets:
trial_id stringlengths 11 11 | source stringclasses 3
values | subsidiary stringlengths 2 68 | sponsor stringlengths 2 105 | official_title stringlengths 16 598 ⌀ | success_prediction float64 0 1 | economic_effect float64 0 1 | duration_prediction float64 -6.13 18.5k | success_composite float64 0.01 1 |
|---|---|---|---|---|---|---|---|---|
NCT00000145 | listed | Bausch & Lomb Incorporated | Bausch & Lomb Incorporated | Age-Related Eye Disease Study (Areds) | 0.91 | 0.52 | 2,626 | 0.760205 |
NCT00000382 | listed | Rochester | University of Rochester | Preventive Intervention For Maltreated Infants | 0.93 | 0.49 | 1,307 | 0.763312 |
NCT00000394 | listed | GW | George Washington University | A Controlled Trial Of Acupuncture For Carpal Tunnel Syndrome | 0.74 | 0.38 | 4,942 | 0.572433 |
NCT00000395 | listed | UAB "AGA" | University of Alabama at Birmingham | Mechanisms Of Antifolate Efficacy In Arthritis | 0.93 | 0.56 | 6,253 | 0.735272 |
NCT00000407 | listed | UAB "AGA" | University of Alabama at Birmingham | Improving Vocational Outcomes In Arthritis | 0.79 | 0.4 | 5,908 | 0.60251 |
NCT00000412 | delisted | Merck Sharp & Dohme L.L.C. | Merck Sharp & Dohme LLC | Prevention Of Osteoporosis After Cardiac Transplantation | 0.93 | 0.61 | 880 | 0.809563 |
NCT00000460 | listed | UAB "AGA" | University of Alabama at Birmingham | Training Levels Comparison (Tlc) Trial In Patients With Coronary Heart Disease | 0.09 | 0.03 | 5,915 | 0.033017 |
NCT00000497 | listed | United HealthCare of Mississippi, Inc | University of Mississippi Medical Center | null | 0.93 | 0.5 | 1,062 | 0.769593 |
NCT00000572 | listed | Intermountain Medical Group, Inc | Intermountain Health Care, Inc. | Extracorporeal Carbon Dioxide Removal for Acute Respiratory Distress Syndrome | 0.91 | 0.54 | 2,569.88 | 0.784992 |
NCT00000577 | listed | Hershey Outpatient Surgery Center, L.P. | Milton S. Hershey Medical Center | Asthma Clinical Research Network (Acrn) | 0.13 | 0.45 | 6,291 | 0.258939 |
NCT00000625 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Randomized, Double-Blind Phase Ii/Iii Trial Of Monotherapy Vs. Combination Therapy With Nucleoside Analogs In Hiv-Infected Persons With Cd4 Cells Of 200-500/Mm3 | 0.95 | 0.77 | 1,095 | 0.855402 |
NCT00000626 | listed | Amgen | Amgen | Phase Ii Study Of Filgrastim (G-Csf) Plus Abvd In The Treatment Of Hiv-Associated Hodgkin'S Disease | 0.94 | 0.54 | 1,095 | 0.771031 |
NCT00000627 | listed | Pfizer | Pfizer | Pilot Study To Determine The Feasibility Of Fluconazole For Induction Treatment And Suppression Of Relapse Of Histoplasmosis In Patients With The Acquired Immunodeficiency Syndrome | 0.94 | 0.58 | 8,036 | 0.695482 |
NCT00000635 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | Treatment Of Acyclovir-Resistant Mucocutaneous Herpes Simplex Disease In Patients With Aids: Open Label Pilot Study Of Topical Trifluridine | 0.93 | 0.53 | 8,036 | 0.672679 |
NCT00000637 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Randomized Comparative Trial Of Zidovudine (Azt) Versus 2',3'-Dideoxyinosine (Ddi) Versus Azt Plus Ddi In Symptomatic Hiv-Infected Children | 0.95 | 0.75 | 8,036 | 0.820722 |
NCT00000638 | listed | Lederle S.L. | Lederle Laboratories | Prophylaxis Against Tuberculosis (Tb) In Patients With Human Immunodeficiency Virus (Hiv) Infection And Confirmed Latent Tuberculous Infection | 0.94 | 0.55 | 8,036 | 0.68522 |
NCT00000640 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Phase Iii Comparative Study Of Dapsone / Trimethoprim And Clindamycin / Primaquine Versus Trimethoprim / Sulfamethoxazole In The Treatment Of Mild-To-Moderate Pcp In Patients With Aids | 0.94 | 0.57 | 8,037 | 0.753449 |
NCT00000644 | listed | Abbott | Abbott | A Phase Ii Safety And Efficacy Study Of Clarithromycin In The Treatment Of Disseminated M. Avium Complex (Mac) Infections In Patients With Aids | 0.92 | 0.53 | 4,133 | 0.731175 |
NCT00000651 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Randomized, Double Blind, Comparative Study Of Dideoxycytidine (Ddc) Alone Or Ddc/Azt Combination Versus Zidovudine (Zdv) Alone In Patients With Hiv Infection Who Have Received Prior Zdv Therapy | 0.94 | 0.57 | 8,036 | 0.753453 |
NCT00000655 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Randomized, Double-Blind Study Of 566C80 Versus Septra (Trimethoprim/Sulfamethoxazole) For The Treatment Of Pneumocystis Carinii Pneumonia In Aids Patients | 0.92 | 0.54 | 1,095 | 0.75963 |
NCT00000656 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Phase I/Ii, Open Label Study To Evaluate The Antiviral Potential Of Combination Zidovudine And 2' 3'-Dideoxyinosine (Didanosine) In Patients With Asymptomatic Hiv Disease | 0.95 | 0.76 | 8,037 | 0.780286 |
NCT00000657 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | Comparison Of 2',3'-Dideoxyinosine (Didanosine, Ddi) And Zidovudine In Therapy Of Patients With The Aids Dementia Complex | 0.95 | 0.73 | 8,037 | 0.796336 |
NCT00000658 | delisted | Schering-Plough A/S | Schering-Plough | A Phase Iii Randomized Trial Of Low-Dose Versus Standard-Dose Mbacod Chemotherapy With Rgm-Csf For Treatment Of Aids-Associated Non-Hodgkin'S Lymphoma | 0.95 | 0.54 | 8,037 | 0.748888 |
NCT00000659 | listed | BIOGEN INC | Biogen | A Phase Ii Trial Of Rscd4 And Azt In Patients With Aids Or Advanced Aids Related Complex (Arc) | 0.08 | 0.1 | 4,150 | 0.105132 |
NCT00000660 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | Phase I Study Of Weekly Oral Vp-16 For Aids-Associated Kaposi'S Sarcoma | 0.94 | 0.62 | 8,037 | 0.726699 |
NCT00000662 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Treatment Ind For Retrovir Brand Zidovudine (Azt) Therapy Of Pediatric Patients With Hiv Disease | 0.79 | 0.06 | 6,208 | 0.440818 |
NCT00000667 | listed | Protein Sciences Corp. | Protein Sciences Corporation | A Phase I/Ii Dose Escalation Study Of Intradermal Gp160 To Evaluate Safety, Delayed Type Hypersensitivity (Skin Test) Responses And Immunogenicity In Asymptomatic Hiv Seropositive Patients With More Than 400 Cd4+ Cells | 0.92 | 0.23 | 8,037 | 0.585464 |
NCT00000669 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Phase I Safety And Pharmacokinetics Study Of 2',3'-Dideoxyinosine (Ddi) Administered Twice Daily To Infants And Children With Aids Or Symptomatic Hiv Infection | 0.92 | 0.58 | 3,220 | 0.72802 |
NCT00000671 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Phase Ii Efficacy Study Comparing 2',3'-Dideoxyinosine (Ddi) (Bmy-40900) And Zidovudine Therapy Of Patients With Hiv Infection Who Have Been On Long Term Zidovudine Treatment | 0.93 | 0.57 | 4,150 | 0.750452 |
NCT00000672 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | An Efficacy Study Of 2',3'-Dideoxyinosine (Ddi) (Bmy-40900) Administered Orally Twice Daily To Zidovudine Intolerant Patients With Aids Or Aids-Related Complex | 0.93 | 0.57 | 4,150 | 0.750452 |
NCT00000674 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Pilot Study Of Oral Clindamycin And Pyrimethamine For The Treatment Of Toxoplasmic Encephalitis In Patients With Aids | 0.94 | 0.54 | 4,581 | 0.699422 |
NCT00000676 | listed | Pfizer | Pfizer | Randomized Comparative Study Of Fluconazole Versus Clotrimazole Troches In The Prevention Of Serious Fungal Infection In Patients With Aids Or Advanced Aids-Related Complex. (A Nested Study Of Actg 081) | 0.95 | 0.6 | 8,036 | 0.769415 |
NCT00000677 | delisted | Schering-Plough A/S | Schering-Plough | Sch 39304 As Therapy For Acute Cryptococcal Meningitis In Hiv-Infected Patients Followed By Maintenance Therapy | 0.92 | 0.52 | 2,061 | 0.716602 |
NCT00000686 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Phase I Safety Study Of Bmy-27857 (2',3'-Dideoxy-2',3'-Didehydrothymidine [D4T]) Administered Four Times Daily To Azt-Intolerant Patients With Aids Or Aids-Related Complex | 0.07 | 0.23 | 3,220 | 0.123745 |
NCT00000721 | listed | BIOGEN INC | Biogen | An Escalating Dose Tolerance Trial Of Bg8962 (Rcd4) In Patients Who Are Hiv Antibody Positive | 0.92 | 0.33 | 731 | 0.666348 |
NCT00000737 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Phase I/Ii Study To Evaluate Single Agent And Combination Therapy With Megestrol Acetate And Dronabinol For The Treatment Of Hiv-Wasting Syndrome | 0.93 | 0.64 | 3,219 | 0.75425 |
NCT00000738 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | Randomized, Double-Blind, Placebo-Controlled Trial Of Nimodipine For The Neurological Manifestations Of Hiv-1 | 0.95 | 0.57 | 8,038 | 0.715294 |
NCT00000741 | listed | Upjohn Inc | Upjohn | A Controlled Randomized Trial To Study The Efficacy Of Adjunctive Methylprednisolone For The Treatment Of Pneumocystis Carinii Pneumonia (Pcp) In Pediatric Aids Patients | 0.12 | 0.09 | 8,038 | 0.121806 |
NCT00000742 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Phase I Concentration-Controlled Trial To Assess The Safety, Tolerance, Pharmacokinetics And Development Of Decreased Hiv-1 Susceptibility To The Combination Of Atevirdine Mesylate (U-87201E), Zidovudine (Azt), And Didanosine (Ddi) | 0.95 | 0.53 | 8,038 | 0.701612 |
NCT00000743 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Phase I, Dose-Escalating Safety And Tolerance Study Of Scd4-Pe40 In Hiv-Infected Persons | 0.93 | 0.55 | 731 | 0.747298 |
NCT00000744 | listed | Pfizer | Pfizer | A Randomized, Prospective, Double-Blind Study Comparing Fluconazole With Placebo For Primary And Secondary Prophylaxis Of Mucosal Candidiasis In Hiv-Infected Women | 0.93 | 0.61 | 8,037 | 0.700038 |
NCT00000745 | listed | Protein Sciences Corp. | Protein Sciences Corporation | A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Safety And Immunogenicity Of Hiv-1 Recombinant Envelope Glycoprotein Gp160 | 0.92 | 0.19 | 8,038 | 0.571559 |
NCT00000748 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Randomized, Comparative, Prospective Study Of Daily Trimethoprim / Sulfamethoxazole (Tms) And Thrice-Weekly Tms For Prophylaxis Against Pcp In Hiv-Infected Patients | 0.94 | 0.55 | 1,062 | 0.792395 |
NCT00000750 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Phase Iii Study To Evaluate The Safety, Tolerance, And Efficacy Of Early Treatment With Zidovudine (Azt) In Asymptomatic Infants With Hiv Infection | 0.94 | 0.53 | 1,062 | 0.785555 |
NCT00000752 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | Management Of Hiv-Infected Patients At Risk Of Recurrent Purulent Sinusitis: Role Of Anti-Inflammatory, Antibacterial, And Decongestant Prophylaxis | 0.13 | 0.42 | 8,031 | 0.222872 |
NCT00000753 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Phase I Concentration-Targeted Multidose Study Of Atevirdine Mesylate ( U-87201E ), Azt, And Ddi Or Ddc | 0.95 | 0.55 | 731 | 0.758699 |
NCT00000754 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Randomized Phase Ii Study Of Two Doses Of Interferon Alfa-2A (Ifn Alfa-2A) In Combination With Zidovudine (Azt) And Dideoxycytidine (Ddc) Versus Azt And Ddc Only In Patients With Hiv Infection And Less Than 400 Cd4 Cells/Mm3 | 0.95 | 0.57 | 8,038 | 0.741605 |
NCT00000755 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Phase I/Ii Trial Of Vaccine Therapy Of Hiv-1 Infected Individuals With 50-500 Cd4 Cells/Mm3 | 0.94 | 0.58 | 8,038 | 0.713013 |
NCT00000757 | listed | Protein Sciences Corp. | Protein Sciences Corporation | A Phase I Multicenter Trial To Evaluate The Safety And Immunogenicity Of Hiv-1 Recombinant Envelope Glycoprotein Gp160 | 0.92 | 0.18 | 8,038 | 0.568083 |
NCT00000765 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | Pilot Study To Evaluate The Efficacy Of Zidovudine In Preventing Cd4+ Lymphocyte Decline In Patients With Primary Hiv Infection. (One Treatment Arm Receives Placebo) | 0.93 | 0.55 | 8,031 | 0.679542 |
NCT00000770 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Comparative Study Of A Combination Of Zidovudine, Didanosine, And Double-Blinded Nevirapine Versus A Combination Of Zidovudine And Didanosine | 0.95 | 0.74 | 8,038 | 0.799752 |
NCT00000772 | listed | ICN Pharmaceuticals, Inc. | ICN Pharmaceuticals | A Phase I Open-Label Study Of The Safety, Tolerance, And Pharmacokinetic Interactions Of Combination Didanosine And Ribavirin In Hiv-Positive Individuals | 0.91 | 0.44 | 8,031 | 0.669745 |
NCT00000781 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Randomized, Double-Blind, Four-Arm Study Comparing Combination Nucleoside, Alternating Nucleoside, And Triple-Drug Therapy For The Treatment Of Advanced Hiv Disease (Cd4 <= 50/Mm3) | 0.95 | 0.74 | 8,038 | 0.799752 |
NCT00000789 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Randomized, Comparative Trial Of Zidovudine (Azt) Versus 2',3'-Didehydro-3'-Deoxythymidine (Stavudine; D4T) In Children With Hiv Infection | 0.95 | 0.75 | 8,038 | 0.803172 |
NCT00000791 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Phase Ii Double-Blind Study Of Two Doses Of Sc-49483 In Combination With Zidovudine (Zdv) Versus Zdv | 0.93 | 0.55 | 8,031 | 0.723394 |
NCT00000799 | listed | Gilead Sciences | Gilead Sciences | Hpmpc (Cidofovir) Peripheral Cmv Retinitis Trial Protocol | 0.94 | 0.52 | 4,748 | 0.69949 |
NCT00000800 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | Methadone Effects On Zidovudine (Zdv, Azt) Disposition | 0.92 | 0.36 | 731 | 0.676609 |
NCT00000807 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | Phase Ii Evaluation Of Low-Dose Oral Etoposide For The Treatment Of Relapsed Or Progressed Aids-Related Kaposi'S Sarcoma After Systemic Chemotherapy | 0.93 | 0.67 | 242 | 0.823866 |
NCT00000811 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Randomized, Phase Ii/Iii, Double-Blind, Two-Armed Study Of Micronized Atovaquone And Azithromycin (At/Az) As Compared To Trimethoprim-Sulfamethoxazole (Tmp/Smx) In The Prevention Of Serious Bacterial Infections When Used In Children Aged 3 Months To 19 Years With Hiv Infection | 0.95 | 0.67 | 730 | 0.82607 |
NCT00000812 | listed | Celgene Corporation | Celgene Corporation | A Phase I, Placebo-Controlled, Dose-Escalation Study Of The Safety, Tolerability, And Pharmacokinetics Of Thalidomide In Subjects With Hiv-1 Infection | 0.93 | 0.58 | 242 | 0.766771 |
NCT00000815 | delisted | Merck Sharp & Dohme L.L.C. | Merck Sharp & Dohme LLC | A Phase Ii, Comparative Study Of Seroconversion Of Single-Dose And Two-Dose Measles Vaccination In Hiv-Infected And Hiv-Uninfected Children: A Multicenter Trial Of The Pediatric Aids Clinical Trials Group | 0.94 | 0.61 | 8,031 | 0.749617 |
NCT00000816 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | Gradual Initiation Of Trimethoprim/Sulfamethoxazole As Primary Pneumocystis Carinii Pneumonia Prophylaxis | 0.92 | 0.54 | 830 | 0.833228 |
NCT00000819 | listed | Upjohn Inc | Upjohn | A Phase Ii Randomized, Double-Blind, Placebo-Controlled Trial To Determine The Efficacy Of Prednisone Therapy In Hiv-Associated Nephropathy (Hivan) | 0.93 | 0.52 | 1,095 | 0.75849 |
NCT00000822 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Phase I/Ii Double-Blind Controlled Trial To Determine The Safety And Immunogenicity Of Hiv-1 Mn Rgp160 Immuno Ag Vaccine Therapy In Hiv-Infected Individuals With Greater Than Or Equal To 500/Mm3 Cd4+ T Cells And 200-400/Mm3 Cd4+ T Cells | 0.93 | 0.49 | 8,032 | 0.676556 |
NCT00000823 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Multicenter Phase Ii Double-Blind Exploratory Study To Evaluate Differences Among Various Zidovudine/Didanosine Regimens On Quantitative Measures Of Viral Burden In Relatively Early Hiv-1 Infection | 0.95 | 0.74 | 91 | 0.864039 |
NCT00000839 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Phase I Trial To Evaluate Didanosine (Ddi) In Hiv-Infected Pregnant Women | 0.94 | 0.63 | 8,032 | 0.730142 |
NCT00000953 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | Evaluation Of Brovavir ( Bv-Ara-U; Sq 32,756 ) Versus Acyclovir In The Treatment Of Localized Herpes Zoster In Hiv-Infected Patients | 0.92 | 0.6 | 4,137 | 0.755093 |
NCT00000954 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | Phase I/Ii Study Of Combination Chemotherapy (Adriamycin, Bleomycin, +/- Vincristine) And Dideoxyinosine (Ddi) Or Dideoxycytidine (Ddc) In The Treatment Of Aids-Related Kaposi'S Sarcoma | 0.95 | 0.66 | 8,032 | 0.746104 |
NCT00000955 | listed | Warner Lambert Co. | Warner Lambert - Parke Davis | Two-Stage Tuberculin (Ppd) Skin Testing In Individuals With Human Immunodeficiency Virus (Hiv) Infection | 0.94 | 0.56 | 5,082 | 0.70337 |
NCT00000956 | listed | Protein Sciences Corp. | Protein Sciences Corporation | A Phase I Multicenter Trial To Evaluate The Safety And Immunogenicity Of Hiv-1 Recombinant Envelope Glycoprotein Gp160 | 0.93 | 0.2 | 8,038 | 0.580827 |
NCT00000960 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Phase Iii Randomized Placebo-Controlled Trial To Evaluate The Efficacy, Safety And Tolerance Of Oral Zidovudine (Azt) In Pregnant Hiv Infected Women And Their Infants | 0.96 | 0.53 | 8,032 | 0.751191 |
NCT00000961 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Phase Ii Study To Evaluate The Safety, Tolerance And Efficacy Of Hyperimmune Anti-Hiv Intravenous Immunoglobulin (Hivig) And Of Zidovudine (Zdv) In Infants With Documented Hiv Infections | 0.07 | 0.1 | 8,038 | 0.079183 |
NCT00000963 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Randomized Comparative Trial Of Two Doses Of 2',3'-Dideoxyinosine (Ddi) In Children With Symptomatic Hiv Infection Who Are Either Unresponsive To Zidovudine And/Or Who Are Intolerant To Zidovudine | 0.94 | 0.65 | 8,032 | 0.763294 |
NCT00000965 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | Pharmacokinetics Of Total Phosphorylated Zidovudine In Mononuclear Cells From Hiv-Infected Patients | 0.53 | 0.23 | 615 | 0.394071 |
NCT00000967 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | Safety And Tolerance Of Zidovudine And Interferon-Alpha In Hiv-Infected Children | 0.94 | 0.55 | 8,032 | 0.702779 |
NCT00000969 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Prospective, Randomized, Open-Label, Comparative Trial Of Dideoxyinosine (Ddi) Versus Dideoxycytidine (Ddc) In Hiv-Infected Patients Who Are Intolerant Of Or Who Have Failed Zidovudine (Azt) Therapy | 0.93 | 0.73 | 8,038 | 0.741078 |
NCT00000973 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | Pyrimethamine Pharmacokinetics In Hiv Positive Patients Seropositive For Toxoplasma Gondii | 0.94 | 0.37 | 8,038 | 0.641184 |
NCT00000975 | listed | Janssen Pharmaceutical | Janssen Pharmaceuticals | Pilot Study To Determine The Feasibility Of Itraconazole For Primary Treatment And Suppression Of Relapse Of Disseminated Histoplasmosis In Patients With The Acquired Immunodeficiency Syndrome | 0.94 | 0.53 | 1,095 | 0.767611 |
NCT00000977 | listed | Protein Sciences Corp. | Protein Sciences Corporation | Active Immunization Of Asymptomatic, Hiv-Infected Individuals With Recombinant Gp160 Hiv-1 Antigen: A Phase I/Ii Study Of Immunogenicity And Toxicity | 0.93 | 0.19 | 8,038 | 0.577351 |
NCT00000979 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | Comparison Of 2',3'-Dideoxyinosine (Ddi) (Bmy-40900) And Zidovudine In Therapy Of Patients With Hiv Infection | 0.93 | 0.58 | 1,095 | 0.779012 |
NCT00000983 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Randomized Blinded Trial To Evaluate The Safety And Tolerance Of High Versus Low Dose Zidovudine Administered To Children With Human Immunodeficiency Virus | 0.95 | 0.54 | 1,095 | 0.776732 |
NCT00000988 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Phase I Safety And Pharmacokinetics Study Of Bmy-27857 (2',3'-Didehydro-3'-Deoxythymidine) Administered Twice Daily To Patients With Aids Or Aids Related Complex | 0.59 | 0.31 | 3,220 | 0.447545 |
NCT00000989 | delisted | Schering-Plough A/S | Schering-Plough | A Controlled, Randomized Phase Ii Study Of The Safety And Efficacy Of Combined Therapy With Ganciclovir And Granulocyte-Macrophage Colony Stimulating Factor Versus Ganciclovir Alone For The Treatment Of Sight-Threatening Cytomegalovirus Retinitis In Aids Patients | 0.94 | 0.56 | 615 | 0.740674 |
NCT00001007 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Multicenter Phase I Trial To Evaluate The Safety And Pharmacokinetics Of Intravenous And Oral Zidovudine In Infants With Perinatal Human Immunodeficiency Virus (Hiv) Exposure | 0.93 | 0.52 | 3,178 | 0.713496 |
NCT00001018 | listed | Janssen Pharmaceutical | Janssen Pharmaceuticals | Blinded, Placebo-Controlled, Single-Dose Pharmacokinetics And Dose Escalation, Efficacy, And Safety Study Of Letrazuril For Aids-Related Cryptosporidial Diarrhea | 0.92 | 0.52 | 2,061 | 0.716602 |
NCT00001024 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Multicenter, Open-Label Study Of Viral Burden In Peripheral Blood Versus Lymphoid Tissue Before And After Antiretroviral Therapy In Hiv-Infected Individuals Without Aids (Note: One Arm Receives No Treatment) | 0.94 | 0.67 | 942 | 0.77357 |
NCT00001025 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Study To Evaluate The Short-Term Clinical And Virologic Significance Of Zidovudine Resistance | 0.94 | 0.73 | 8,035 | 0.790644 |
NCT00001029 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Randomized, Double-Blind, Three-Arm Study Comparing Combination To Monthly Alternating Nucleoside Therapy For The Treatment Of Advanced Hiv Disease (Cd4 <= 50/Mm3) With A Prior History Of Nucleoside Therapy | 0.94 | 0.74 | 1,095 | 0.83944 |
NCT00001035 | delisted | Schering-Plough A/S | Schering-Plough | A Phase I Pilot Study Of The Safety And Efficacy Of Interferon Alfa-2B (Ifn Alfa-2B) In Combination With Nucleoside Analog Therapy In Patients With Combined Hepatitis C (Hcv) And Advanced Human Immunodeficiency Virus (Hiv) Infections | 0.95 | 0.53 | 4,563 | 0.719349 |
NCT00001038 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Randomized, Double-Blind Trial Of Valacyclovir Hydrochloride (Bw 256U87) Prophylaxis For Opportunistic Cytomegalovirus End-Organ Disease In Patients With Advanced Hiv Infection (< 100 Cd4+ Lymphocytes) | 0.93 | 0.52 | 4,137 | 0.750971 |
NCT00001045 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Double-Blinded, Randomized Trial Comparing Zidovudine (Azt) Versus Azt Plus Didanosine (Ddi) Versus Azt Plus Ddi Plus Nevirapine In Asymptomatic Patients On Azt Monotherapy Who Develop A Mutation At Codon 215 Of Hiv Reverse Transcriptase In Serum/Plasma Viral Rna | 0.95 | 0.7 | 8,038 | 0.78607 |
NCT00001048 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Phase Ii Multicenter Study Comparing Antiretroviral Therapy Alone To Antiretroviral Therapy Plus Cytosine Arabinoside (Cytarabine; Ara-C) For The Treatment Of Progressive Multifocal Leukoencephalopathy (Pml) In Human Immunodeficiency Virus (Hiv)-Infected Subjects | 0.95 | 0.66 | 1,095 | 0.817777 |
NCT00001054 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Phase I Trial To Evaluate The Pharmacokinetics, Safety, And Tolerance Of Valacyclovir Hcl In Hiv-1 Infected Children With Herpes Simplex Infections Or Varicella/Zoster Infections | 0.09 | 0.07 | 8,038 | 0.054012 |
NCT00001059 | listed | Amgen | Amgen | Comparison Study Of Liposomal Doxorubicin With Or Without Bleomycin And Vincristine For The Treatment Of Advanced Aids-Associated Kaposi'S Sarcoma | 0.95 | 0.64 | 1,095 | 0.810936 |
NCT00001061 | listed | Facet Biotech Corporation | Facet Biotech | A Phase Ii, Double-Masked, Randomized, Placebo-Controlled Evaluation Of Standard Therapy Vs. Standard Therapy Combined With Human Monoclonal Anti-Cytomegalovirus Antibody (Msl 109) In The Therapy Of Aids Patients With Cytomegalovirus (Cmv) Retinitis | 0.96 | 0.54 | 8,035 | 0.737057 |
NCT00001063 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Phase Ii Randomized Study Of The Virologic And Immunologic Effects Of D4T Vs Zidovudine Plus D4T Vs Zidovudine Plus Ddl In Hiv-Infected Patients With Cd4 Cell Counts Between 300-600/Mm3 And Greater Than 12 Weeks Zidovudine Experience | 0.95 | 0.65 | 8,038 | 0.768968 |
NCT00001065 | listed | BRISTOL MYERS SQUIBB | Bristol-Myers Squibb | A Phase Ii Trial Of Amphotericin B Oral Suspension For Fluconazole-Resistant Oral Candidiasis In Hiv-Infected Patients | 0.94 | 0.67 | 1,095 | 0.815497 |
NCT00001066 | listed | GLAXOSMITHKLINE PLC | Glaxo Wellcome | A Randomized Comparative Study Of Combined Zidovudine-Lamivudine (3Tc) Vs. The Better Of Ddi Monotherapy Vs. Zidovudine Plus Ddl In Symptomatic Hiv-1 Infected Children | 0.94 | 0.62 | 426 | 0.808386 |
NCT00001114 | delisted | Schering-Plough A/S | Schering-Plough | A Randomized Phase Ii Trial To Determine The Safety, Tolerance, And Efficacy Of Two Doses Of Interferon Alfa-2B Combined With Didanosine In Patients With Kaposi'S Sarcoma | 0.94 | 0.66 | 8,035 | 0.766701 |
NCT00001128 | listed | GENETICS INSTITUTE, INC. | Genetics Institute | A Pilot, Proof-Of-Concept, Dose-Escalating Trial Of Recombinant Human Interleukin-12 (Rhil-12) Versus Placebo Along With Paromomycin And Azithromycin For Chronic Cryptosporidiosis In Aids | 0.09 | 0.03 | 6,176 | 0.03167 |
Stocks Weekly PharmaClinicalPredict
Modelled outcome, duration and economic impact for pharmaceutical clinical trials, one row per trial.
91,981 rows, 9 columns. Updated by Papers With Backtest.
Why It Matters
A biotech's value is a probability-weighted pipeline, and the probabilities are what this dataset estimates:
- Event odds ahead of the readout:
success_predictionis a modelled probability that a trial reaches its endpoint. Priced against the sponsor's market capitalisation, it is a view on how much of the outcome is already in the stock. - Timing:
duration_predictionestimates how long the trial still has to run, which is what decides whether an event is inside or outside a holding period. - Size of the move:
economic_effectscores how material the trial is to the sponsor, separating a phase III lead asset from a minor indication.
Load It
Installation/Upgrade:
pip install --upgrade pwb-toolbox
Load the Dataset:
from pwb_toolbox import datasets as pwb_ds
predictions = pwb_ds.load_dataset("Stocks-Weekly-PharmaClinicalPredict")
trials = pwb_ds.load_dataset("Stocks-Weekly-PharmaClinicalTrials")
# The predictions carry no ticker; the trial register is what maps them to one.
linked = predictions.merge(
trials[["trial_id", "symbol", "datetime"]].drop_duplicates("trial_id"),
on="trial_id",
how="inner",
)
Columns
| Column Name | Description |
|---|---|
| trial_id | Registry identifier for the trial. The join key to Stocks-Weekly-PharmaClinicalTrials. |
| source | Registry the trial was read from. |
| sponsor | Sponsoring organisation. |
| subsidiary | Subsidiary running the trial, where it differs from the sponsor. |
| official_title | Registered title of the trial. |
| success_prediction | Modelled probability, between 0 and 1, that the trial meets its endpoint. |
| success_composite | Composite score combining the success model with trial characteristics. |
| duration_prediction | Modelled remaining duration, in days. |
| economic_effect | Unitless index of how material the outcome is to the sponsor. |
What This Data Does Not Cover
There is no ticker and no date column. The file is one row per trial, keyed by trial_id, and it carries neither symbol nor datetime. Mapping a prediction to a listed company means joining Stocks-Weekly-PharmaClinicalTrials, which holds both. Anything that needs a point-in-time view has to take its timestamps from that side too.
Access
Browsing the card and the schema is open to anyone. Downloading the files needs an approved request, tied to a subscription: what each plan includes. The same subscription covers the other datasets in this organisation.
Elsewhere
- Dataset page and coverage charts
- The strategy catalogue, 3,806 papers and 4,837 replicated strategies
pwb-toolbox, the loader used in the snippet aboveawesome-systematic-trading, the replicated strategies with their measured Sharpe- Every dataset in this organisation
Papers With Backtest publishes 32 datasets on the Hub and codes the papers that use them. Every strategy in the catalogue is run over its own full history before it is published, which is where the numbers above come from.
- Downloads last month
- 78